Investigational Inhibitor of Active RAS Shows Clinical Promise
The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C...
The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C...
Second-generation PRMT5 inhibitor targets synthetic lethality in several cancer types with MTAP loss BOSTON – AMG 193, a second-generation...
ORLANDO, Fla. – The American Association for Cancer Research (AACR) will award Folakemi T. Odedina, PhD, with the 2023...
ORLANDO, Fla. – Compared to the year 2000, a greater proportion of NCI-sponsored early-phase clinical trial participants in 2022...
ORLANDO, Fla. – Structural racism was associated with increased county-level cancer mortality rates among minority populations compared with whites,...
Survey found that most people are open to participating, and motivation varied by racial and ethnic group ORLANDO, Fla....
Most men in survey were never offered the HPV vaccine ORLANDO, Fla. – A study found multiple gaps in...
Palliative care use increased among all racial/ethnic groups from 2004 to 2020 ORLANDO, Fla. – Despite a steady increase...
Researchers applied single-nucleus RNA sequencing and spatial transcriptomics to identify potential therapeutic targets in brain metastases ORLANDO, Fla. –...
ORLANDO, Fla. – A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical...